我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 打开 J 门
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Breaking Bad News: Preferences of Cancer Patients in Saudi Arabia

Syed Mustafa Karim, Jamal M Zekri, Sawsan Bassi, Baker bin Sadiq, Ehab M Abdelghany, Hossam Abdelrahman and Elshami Elamin

Background: It is believed in some Middle Eastern (ME) cultures that disclosure of bad news to cancer patients may cause loss of hope. This is often used to justify withholding such news. In this study, we examine cancer patients ‘preference regarding breaking bad news and disease information disclosure to them. Patients and Methods: Nine close ended questions addressing patient’s disclosure preference and one question addressing timing of disclosure to the family were designed in a questionnaire format and were answered by cancer patients in an outpatient setting. Affirmative “Yes” answer indicates preference to be informed of bad news. Results: One hundred patients were recruited and answered the questions. 87% of patients preferred to be informed of their cancer diagnosis. There was no statistically significant effect of age, gender, education level, professional status, diagnosis and stage of disease on this preference. 98% wanted to know of serious news about their health. 60% of patients answered “Yes” to 8 or 9 questions. Age ≥ 50 compared to <50 years was the only factor significantly associated with likelihood of affirmative response to 8 or 9 questions (Chi2 P=0.027). Conclusions: Our study indicates that most cancer patients in Saudi Arabia prefer to know the diagnosis of cancer and any related poor outcomes, and to be involved in decision making throughout the course of their illness. This is in congruence with results of other studies from other parts of the world. Given this accumulating body of evidence, healthcare provider should, whenever possible, keep the patients involved in the decision making process throughout the cancer journey.